Efectos glucémicos y de pérdida de peso de la terapia con agonistas de GLP-1R en sujetos con lesión de la médula espinal y diabetes tipo 2
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This study consists of 7-9 in-person visits and 9-10 phone visits, and participants will be randomized to either semaglutide or placebo for 24 weeks. The participants first visit, will include review of medical history and performance of standard tests to check the participant's health and eligibility for the study. Before starting any medication, participants will have 2 more visits:
- a mixed meal tolerance test, to examine their body's response to nutrient ingestion and
- a glucose clamp study to examine insulin sensitivity. These tests will be scheduled on two separate days. Following the 3 baseline visits, participants will be randomized to either the intervention (once-weekly injection of semaglutide, also known as Ozempic, for 24 weeks) or placebo. During the 24-week intervention participants will receive 9-10 phone calls to discuss their progress and experiences with the interventions and will also be asked to return for a short research visit including interim medical history with or without blood sample collection twice. At the end of 24 weeks, the treatments will be discontinued, and participants will repeat the meal and glucose studies scheduled over two separate days. During participation, fat/lean mass will be measured using DEXA and liver fat mass may be measured using fibroscan. In addition, participants may be asked for a stool sample.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Marzieh Salehi, MD
- Número de teléfono: 210-567-6691
- Correo electrónico: salehi@uthscsa.edu
Copia de seguridad de contactos de estudio
- Nombre: Andrea Hansis-Diarte, MPh
- Número de teléfono: 210 567 3208
- Correo electrónico: hansisdiarte@uthscsa.edu
Ubicaciones de estudio
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- University of Texas Health Science Center at San Antonio
-
Investigador principal:
- Marzieh Salehi, MD, MS
-
Contacto:
- Mooney Mark-Johnson
- Correo electrónico: markjohnson@uthscsa.edu
-
Contacto:
- Hector Gonzalez Cantu, PhD
- Número de teléfono: 2105676707
- Correo electrónico: gonzalezcant@uthscsa.edu
-
San Antonio, Texas, Estados Unidos, 78207
- Reclutamiento
- University Health - Texas Diabetic Institute
-
Investigador principal:
- Marzieh Salehi, MD, MS
-
Contacto:
- Mooney Mark-Johnson
- Correo electrónico: markjohnson@uthscsa.edu
-
Contacto:
- Hector Gonzalez Cantu, PhD
- Número de teléfono: 2105676707
- Correo electrónico: gonzalezcant@uthscsa.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male and female subjects aged 18-70 years (inclusive) at screening
- More than one year after spinal cord injury
- Levels if injury C2-L2 with Asia Impairment Scale A, B, C or D.
- Provision of signed and dated written informed consent prior to any study specific procedures
- Diagnosed with T2DM with glucose control managed with diet and metformin monotherapy where no significant dose changes (increase or decrease ≥ 50%) have occurred in the three months prior to screening
- HbA1c 6.0-9.0% at screening
- BMI > 22 kg/m2 at screening
- Female subjects of childbearing potential must have a negative pregnancy test at screening and randomization, and must not be lactating
- Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions through to the end of the study. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
Exclusion Criteria:
-
History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures.
-
Any subject who has received another investigational product as part of a clinical study within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening
-
Taking mirabegron or other glucose altering medications
-
Taking steroids within the past 1 year
-
Significant anemia (hemoglobin<11g/dL)
-
History of gastric outlet obstruction or chronic diarrhea
-
History of a chronic neurological illness other than SCI (i.e.; MS, etc)
-
Any subject who has received any of the following medications within the specified time-frame prior to the start of the study
- Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within a year prior to the start of the study
- Pioglitazone, SGLT2 or DPPIV inhibitors, GLP-1RA within the last 60 days at the time of screening
-
Severe allergy/hypersensitivity to any of the proposed study treatments, excipients, acetaminophen
-
Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening.
-
Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract (including weight-reducing surgery and procedures) which could affect the interpretation of safety and tolerability data. Prior history of bariatric surgery is not considered exclusion given the ample evidence of safety of use of GLP-1R therapy in this population.
-
Acute or chronic pancreatitis
-
Significant hepatic disease (except for metabolic dysfunction-associated steatohepatitis [MASH] or metabolic dysfunction-associated steatotic liver disease [MASLD]) without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:
Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
-
Impaired renal function defined as estimated glomerular filtration rate (eGFR) < 45 mL/minute/1.73m2 at screening (GFR estimated according to Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation IDMS-traceable [SI units])
-
Unstable angina pectoris, myocardial infarction, transient ischemic attack (TIA) or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening
-
Severe congestive heart failure (New York Heart Association Class III or IV)
-
Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia
-
History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer
-
History of HIV infection or other immune compromised disease; and history of organ transplantation
-
Substance dependence or history of alcohol abuse and/or excess alcohol intake
-
Patients on ketogenic diet
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: SCI and T2DM Treatment Group
Participants with spinal cord injury (SCI) and type 2 diabetes (T2DM) will be assigned to semaglutide weekly for 24 weeks. Semaglutide administration: once-weekly self-administration of SGT, titrated to a dose of 2 mg/week as per FDA approved guidelines. All subjects will be instructed how to inject and titrate up the dose. |
A GLP-1 inhibitor used to control T2DM
Otros nombres:
|
|
Comparador de placebos: SCI and T2DM Placebo Group
Participants with spinal cord injury (SCI) and type 2 diabetes (T2DM) will be assigned to the placebo group and inject normal saline weekly for 24 weeks. All subjects in the placebo group will be instructed how to inject and titrate up the dose to mimic the semaglutide administration to a maximum dose of 2 mg in 12 weeks and then continue for remainder of study. |
Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Glucose tolerance
Periodo de tiempo: Baseline to 24 weeks
|
The change in the incremental AUC Glucose3h response to meal ingestion |
Baseline to 24 weeks
|
|
Insulin action
Periodo de tiempo: Baseline to 24 weeks
|
Liver, adipose tissue and muscle insulin sensitivity determined using a two-step euglycemic clamp. |
Baseline to 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Marzieh Salehi, MD, The University of Texas Health Science Center at San Antonio
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Heridas y Lesiones
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Trauma, Sistema Nervioso
- Enfermedades de la médula espinal
- Enfermedades Nutricionales y Metabólicas
- Diabetes Mellitus, Tipo 2
- Lesiones de la médula espinal
- Preparaciones farmacéuticas
- Soluciones cristaloides
- Soluciones isotónicas
- Soluciones
- Solución salina
- semaglutida
Otros números de identificación del estudio
Otros números de identificación del estudio
- STUDY00000591
- R01DK140144-02 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The shared data will be de-identified according to HIPAA and shared under a repository standard Data Use Agreement (DUA).(e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant). Plans for archiving and long-term preservation of the data will be implemented, as appropriate.ccess to shared data will be controlled according to the repository policy which requires a request and merit review and will be available according to repository processes. The shared data will be de-identified according to HIPAA and shared under a repository standard Data Use Agreement (DUA).
Marco de tiempo para compartir IPD
Study data will be shared as summary results on ClinicalTrials.gov a year after the primary completion date and full results will be shared at study end after data has been analyzed and published in a peer review journal.
Criterios de acceso compartido de IPD
The scientific data generated from this study will be shared in the Texas Digital Library
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .